Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 04, 2025 16:05 ET | Source: Syndax Pharmaceuticals, Inc. NEW YORK,…
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance…
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Breaking Barriers in Autism: European Wellness Biomedical Group Unveils Bioregenerative Breakthroughs with Prof. Mike Chan
BAODING, China, April 05, 2025 (GLOBE NEWSWIRE) -- European Wellness Biomedical Group…
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA),…
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinsons Disease at AD/PD 2025
April 01, 2025 08:15 ET | Source: Cerevance, Inc. Solengepras showed evidence…
Nkarta to Participate in an April Investor Conference
April 01, 2025 08:01 ET | Source: Nkarta, Inc. SOUTH SAN FRANCISCO,…
VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer
~ Appointment Strengthens Clinical Leadership as VectorY Prepares to Submit Investigational New…
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
March 28, 2025 21:35 ET | Source: Junshi Biosciences SHANGHAI, March 28,…
Strategic update on the progress and development of Molecure’s key clinical projects in 2024
Molecure achieved key milestones in the development of its innovative therapies in…